This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Desonide

Dosage Form; Route: Aerosol foam; topical

Recommended Studies: Two studies

1. Type of study: Pilot Vasoconstrictor Study
   Design: A pilot dose duration-response study using the reference product
   Strength: 0.05%
   Subjects: Males and non-pregnant, non-lactating females, general population

   Additional comment: Refer to the guidance “Topical Dermatological Corticosteroids: In Vivo Bioequivalence”.

2. Type of study: Pivotal vasoconstrictor study
   Design: A pivotal bioequivalence study
   Strength: 0.05%
   Subjects: Males and non-pregnant, non-lactating females, general population

   Additional Comment: See comments above

Analytes to measure (in appropriate biological fluid): Not applicable

Bioequivalence based on (90% CI): Pivotal vasoconstrictor study

Waiver request of in vivo testing: Not applicable

Dissolution test method and sample times: Not applicable

Recommended Feb 2018